AUSTIN, Texas--(BUSINESS WIRE)--
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced the publication of Outcomes of Endoscopic Gastroplasty (“ESG”) in 1,000 Consecutive Patients from a single center - King Saud University, Riyadh, Saudi Arabia featured in Gastrointestinal Endoscopy (GIE) - https://doi.org/10.1016/j.gie.2018.12.012.
ESG is an endoscopic minimally invasive weight loss procedure based on full-thickness endoscopic suturing using Apollo’s OverStitch™ device. In the ESG procedure, a series of sutures are placed through the gastric wall reducing the stomach volume by 80% creating a restrictive endoscopic sleeve. The result allows a patient to consume less food and remain satiated longer.
“Our experience has been that patients find the ESG procedure very appealing and for our practice it is now an established option for our patients. In these first 1,000 consecutive patients that we treated with Endoscopic Sleeve Gastroplasty, patients experienced a 100% remission for hypertension related comorbidities, a 70% remission rate for type 2 diabetes with the remaining 30% showing significant improvement, and we confirmed that ESG is a safe, well-tolerated, and effective procedure. In addition, we also achieved 64.7% excess weight loss at 18 months follow-up, which is comparable to results achieved with other surgical bariatric interventions,” said Dr. Aayed AlQahtani, Professor of Surgery at King Khalid University Hospital and Director of Obesity Chair at King Saud University.
Key data reported from the 1,000 patients who underwent the ESG procedure include:
- Mean age was 34.4 ±9.5 years, and mean BMI was 33.3 ±4.5 kg/m2
- Mean % total weight loss at 18 months was 14.8 ±8.5%
- Significant impact to obesity related comorbidities occurred by month three:
- 13 of 17 cases of type 2 diabetes were in complete remission
- All 28 cases of hypertension were in complete remission
- 18 of 32 cases of dyslipidemia were in complete remission
- 24 (2.4%) patients were admitted to the hospital due to postoperative complaints. No patient required an emergency intervention and there were no mortalities.
The OverStitch endoscopic suturing system enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures from a flexible endoscope. This new technology enables a secure approximation of tissue endoscopically and a wide range of less invasive solutions for physicians who treat defects in both the upper and lower GI tract of their patients. Additionally, physicians are leveraging endoscopic suturing to perform a variety of advanced bariatric procedures. For more information regarding OverStitch go to: www.apolloendo.com.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Apollo’s common stock is traded on Nasdaq Global Market under the symbol "APEN." For more information regarding Apollo, go to: www.apolloendo.com.
© 2018 Apollo Endosurgery, Inc. All rights reserved. Any third-party trademarks used herein are the property of their respective owners.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: reports of adverse events related to our products, developments in medical technology, regulatory approvals and extensive regulatory oversight by the FDA or other regulatory bodies, unfavorable media coverage related to our products or related procedures, reimbursement decisions by private or government payors, physician adoption and recommendations of procedures utilizing our products and other factors detailed from time to time in the reports Apollo files with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2017, and its Form 10-Q for the three months ended September 30, 2018. Copies of reports filed with the SEC are posted on Apollo’s website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.